We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+5%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$40.3B
AUM Growth
+$535M
(+1.3%)
Cap. Flow
-$468M
Cap. Flow
% of AUM
-1.16%
Top 10 Holdings %
Top 10 Hldgs %
15.78%
Holding
2,279
New
170
Increased
711
Reduced
1,071
Closed
189
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$178M |
| 2 |
LyondellBasell Industries
LYB
|
+$133M |
| 3 |
AT&T
T
|
+$124M |
| 4 |
Stanley Black & Decker
SWK
|
+$101M |
| 5 |
Pfizer
PFE
|
+$93.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Clorox
CLX
|
+$229M |
| 2 |
Gilead Sciences
GILD
|
+$164M |
| 3 |
Broadcom
AVGO
|
+$149M |
| 4 |
KeyCorp
KEY
|
+$145M |
| 5 |
Darden Restaurants
DRI
|
+$125M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.22% |
| 2 | Technology | 14.47% |
| 3 | Financials | 10.84% |
| 4 | Industrials | 9.01% |
| 5 | Consumer Discretionary | 8.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1451
Delek US
DK
$4.85B
| $359K | ﹤0.01% |
15,008
-154,990
| -91% | -$3.52M |
|
1452
EyePoint Inc
EYPT
$297M
| $359K | ﹤0.01% |
+41,261
| New | +$252K |
|
1453
SOPHiA GENETICS
SOPH
$678M
| $358K | ﹤0.01% |
80,000
+15,487
| +24% | +$70K |
|
1454
TriNet
TNET
$3.18B
| $353K | ﹤0.01% |
3,721
-589
| -14% | -$53.6K |
|
1455
Mineralys Therapeutics
MLYS
$2.43B
| $351K | ﹤0.01% |
+20,593
| New | +$308K |
|
1456
CBRE Group
CBRE
$40.1B
| $351K | ﹤0.01% |
4,350
+399
| +10% | +$29.9K |
|
1457
Crane NXT
CXT
$2.72B
| $350K | ﹤0.01% |
6,207
-9,829
| -61% | -$500K |
|
1458
Thomson Reuters
TRI
$43.9B
| $350K | ﹤0.01% |
+2,549
| New | +$342K |
|
1459
Aon
AON
$63.8B
| $348K | ﹤0.01% |
1,009
-133
| -12% | -$43.2K |
|
1460
Texas Capital Bancshares
TCBI
$4.14B
| $346K | ﹤0.01% |
6,727
+2,335
| +53% | +$116K |
|
1461
NewMarket
NEU
$8.2B
| $344K | ﹤0.01% |
856
-90
| -10% | -$35.1K |
|
1462
Associated Banc-Corp
ASB
$5.62B
| $344K | ﹤0.01% |
21,203
-2,111
| -9% | -$34.8K |
|
|
BKI
1463
DELISTED
Black Knight, Inc. Common Stock
BKI
| $341K | ﹤0.01% |
5,701
+1,403
| +33% | +$78.8K |
|
1464
Papa John's
PZZA
$665M
| $339K | ﹤0.01% |
4,596
-85
| -2% | -$6.3K |
|
1465
Werner Enterprises
WERN
$2.15B
| $334K | ﹤0.01% |
7,571
-272
| -3% | -$12.2K |
|
1466
Beyond Meat
BYND
$188M
| $332K | ﹤0.01% |
853
-710
| -45% | -$271K |
|
1467
Cathay General Bancorp
CATY
$4.14B
| $328K | ﹤0.01% |
10,193
+459
| +5% | +$14.6K |
|
1468
International Bancshares
IBOC
$4.41B
| $328K | ﹤0.01% |
7,419
+139
| +2% | +$6.05K |
|
1469
Assured Guaranty
AGO
$3.14B
| $326K | ﹤0.01% |
5,838
-1,007
| -15% | -$53.5K |
|
1470
Graham Holdings Company
GHC
$4.81B
| $325K | ﹤0.01% |
569
+58
| +11% | +$33.6K |
|
1471
Knife River
KNF
$3.16B
| $325K | ﹤0.01% |
+7,470
| New | +$317K |
|
1472
TXO Partners LP
TXO
$821M
| $325K | ﹤0.01% |
15,000
-11,000
| -42% | -$245K |
|
1473
Acadia Pharmaceuticals
ACAD
$4.75B
| $320K | ﹤0.01% |
13,366
+13,307
| +22,554% | +$296K |
|
1474
Beam Therapeutics
BEAM
$2.39B
| $319K | ﹤0.01% |
10,000
| – | – |
|
1475
Autodesk
ADSK
$46B
| $315K | ﹤0.01% |
1,540
-34
| -2% | -$6.8K |
|
Similar funds
Federated Hermes's Q2 2023 Portfolio in Review
As of Q2 2023, Federated Hermes held 2,279 positions worth $40.3B, up 1.3% from $39.7B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Federated Hermes's Q2 2023 filing shows 170 new, 711 increased, 1,071 reduced and 189 closed positions. Its largest new stake was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M. The largest sale was Clorox, an estimated $229M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 20% a quarter earlier, followed by Technology and Financials.
- Federated Hermes's largest Q2 2023 buy was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M.
- Federated Hermes added most to Amgen in Q2 2023, an estimated $178M increase.
- Federated Hermes's biggest Q2 2023 reduction was Clorox, cutting an estimated $229M.
- Federated Hermes fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $55.4M.
- Federated Hermes's ten largest holdings make up 16% of its $40.3B portfolio in Q2 2023.
- Federated Hermes opened 170 new positions and closed 189 in Q2 2023.
- Federated Hermes's portfolio value rose 1.3% quarter-over-quarter to $40.3B.
Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.